Insulet (Nasdaq:PODD) announced that it successfully defended its intellectual property against EOFlow in U.S. federal court. Both companies develop automated insulin delivery systems utilizing patch pump technology. Insulet offers the market-leading Omnipod platform, while Korea-based EOFlow develops the EOPatch — similarly, a tubeless, wearable and fully disposable insulin delivery device. EOFlow was at one point […]
Insulet
Insulet Omnipod 5 is now compatible with Abbott FreeStyle Libre 2 Plus in the U.S.
Insulet (Nasdaq:PODD) today announced compatibility between its Omnipod 5 insulin pump and the Abbott (NYSE:ABT) FreeStyle Libre 2 Plus CGM in the U.S. The company says this latest integration makes Omnipod 5 the most connected tubeless automated insulin delivery system in the U.S. Compatibility in the U.S. comes about eight months after the company integrated […]
The biggest diabetes tech stories of the year so far
On World Diabetes Day, it’s worth taking a look back at the last 10.5 months in the diabetes technology space. The date, which marks the birth date of the inventor of insulin, brings out all sorts of initiatives from various companies involved in innovating these technologies (read about those HERE). Those companies have contributed to […]
What diabetes tech companies are doing on World Diabetes Day 2024
World Diabetes Day — today, Nov. 14 — brings out the best in the diabetes community that continues to innovate year after year. This date serves as a time to recognize these innovations as it marks the birthday of Sir Frederick Banting. Banting discovered the insulin hormone along with Charles Herbert Best in 1922. The […]
Insulet stock rises on Q3 beat, raised sales guidance
Insulet (Nasdaq:PODD) shares ticked up today on third-quarter results that came in well ahead of the consensus forecast. Shares of PODD rose 3.3% to $257 apiece in post-market trading today. The Acton, Massachusetts-based automated insulin delivery system maker reported profits of $77.5 million. That equals $1.08 per share on sales of $543.9 million for the […]
Insulet announces diabetes awareness initiatives for November
Insulet (Nasdaq:PODD) today announced its plans to recognize National Diabetes Awareness Month and World Diabetes Day. National Diabetes Awareness Month takes place over the course of the entire month of November. World Diabetes Day lands on Nov. 14 every year, marking the birthday of Sir Frederick Banting. Banting discovered the insulin hormone along with Charles […]
Insulet fully launches Omnipod 5 app for iPhone in U.S.
Insulet (Nasdaq:PODD) today announced the full market release of the Omnipod 5 automated insulin delivery app for iPhone in the U.S. Acton, Massachusetts-based Insulet now offers the app for free download from the Apple App Store. It allows users to fully control their Omnipod 5 patch pump from their compatible iPhone. For example, users can […]
FDA clears Insulet Omnipod 5 for people with type 2 diabetes
Insulet (Nasdaq:PODD) announced today that the FDA cleared its Omnipod 5 automated insulin delivery for use by people with type 2 diabetes. Clearance makes Omnipod 5, the company’s latest-generation AID system, the first and only such system cleared for type 1 and type 2 diabetes. Its indication covers those ages 18 and older in the […]
Former Medtronic acquisition target EOFlow to raise $61.5M, faces Insulet patent infringement lawsuit
EOFlow faces a patent infringement lawsuit from fellow insulin patch pump maker Insulet as it attempts to bring in millions in a new funding round. The Korea-based company develops the EOPatch — a tubeless, wearable and fully disposable insulin delivery device. EOFlow was at one point set to be acquired by Medtronic for $738 million last […]
The 9 largest diabetes technology companies in the world
Diabetes technology comes in all shapes and sizes: insulin delivery systems, continuous glucose monitors and more. The companies that develop these technologies come in all shapes and sizes, too. Some focus entirely (or almost entirely) on solutions for people with diabetes. Others are much larger medtech firms that still have sizable business units that focus […]
